Basic Avana Information

• INN (International Nonproprietary Name): Avanafil
• Brand Names Available In United Kingdom: Spedra (foil blisters, tablets; 50 mg, 100 mg, 200 mg)
• ATC Code: G04BE11
• Forms & Dosages: Oral Tablets 50 mg, 100 mg, 200 mg
• Manufacturers In United Kingdom: Menarini Group (licensed distribution)
• Registration Status In United Kingdom: Authorised as Spedra
• OTC / Rx Classification: Prescription only (Rx)

Key Findings From Recent Trials

Worried about how fast avana works and whether it is safe?

Major 2022–2025 Studies

Recent randomised, placebo‑controlled phase II/III trials from 2022–2025 highlight avanafil’s rapid onset and good tolerability in men with erectile dysfunction.

Large multicentre studies recruiting across Europe and North America report significant improvements in the erectile function domain of the International Index of Erectile Function compared with placebo.

Many participants experienced clinically meaningful responses as early as 15 minutes after dosing, supporting avanafil’s positioning as a rapid‑onset option.

Subgroup analyses showed benefit across age groups and baseline ED severity when dosed at the typical starting dose of 100 mg, aligning with Spedra 100 mg practice in the UK.

Real‑world observational cohorts back up trial findings, with effectiveness maintained over several months on on‑demand dosing.

Main Outcomes

Primary endpoints in recent trials focused on successful vaginal penetration and intercourse rates measured over the study period.

Secondary endpoints included patient satisfaction metrics and partner reports of sexual fulfilment and confidence.

Pooled analyses show a favourable number needed to treat compared with much earlier PDE5 inhibitor trials, indicating good clinical value for appropriate patients.

Safety Observations

Adverse events were predominantly mild and included headache, flushing and nasal congestion.

No signal of increased serious cardiovascular events emerged in carefully screened trial populations, though standard cardiac precautions remain essential.

UK clinicians commonly note a quicker onset compared with sildenafil, and Spedra is marketed in 50 mg, 100 mg and 200 mg strengths consistent with trial regimens.

Clinical Mechanism Of Action

Curious how avana actually helps an erection without creating arousal?

Layman’s Explanation

Avanafil is a selective phosphodiesterase type‑5 inhibitor that boosts blood flow to the penis by enhancing nitric oxide‑mediated cGMP signalling during sexual stimulation.

The drug helps men achieve and maintain erections but does not cause sexual desire on its own.

Scientific Breakdown

Avanafil selectively inhibits PDE5 in corpus cavernosum smooth muscle, preventing the breakdown of cGMP and promoting vasodilation that enables erection during sexual stimulation.

Compared with sildenafil and vardenafil, avanafil demonstrates higher PDE5 selectivity and lower PDE6 cross‑reactivity, which correlates clinically with fewer visual disturbances.

Pharmacokinetics show oral tablets in 50 mg, 100 mg and 200 mg strengths with a typical Tmax around 30–45 minutes, and clinically meaningful responses documented at around 15 minutes for some men.

Metabolism is mainly hepatic via CYP3A4, with minor contributions from CYP2C and non‑CYP pathways.

The half‑life supports on‑demand rather than routine daily dosing.

Molecular Selectivity Implications

Greater PDE5 selectivity reduces off‑target effects and is associated with a lower incidence of PDE6‑mediated visual side effects compared with older agents.

PK Considerations For Clinicians

Use caution with strong CYP3A4 inhibitors and consider a lower starting dose such as 50 mg in patients with significant interactions or hepatic impairment.

In the UK, Spedra is available in 50/100/200 mg tablets and remains prescription‑only, so prescribers should document counselling and review concomitant medicines.

Scope Of Approved And Off‑Label Use

What is Spedra licensed for in the UK and when might clinicians consider off‑label use?

United Kingdom Approvals

Avanafil is authorised in the UK as Spedra for the treatment of erectile dysfunction and is supplied in foil blisters in 50 mg, 100 mg and 200 mg strengths.

UK clinicians follow EMA and MHRA guidance aligned with the licensed indication for on‑demand use prior to sexual activity.

Notable Off‑Label Trends

Off‑label avanafil use is limited but occurs in specific scenarios such as prior intolerance to other PDE5 inhibitors or priority for a fast onset.

Case series describe exploratory use after prostatectomy and combined with psychosexual therapy, although formal evidence is sparse.

Clinical governance requires documenting informed consent for off‑label prescribing, thorough cardiovascular screening, and strict avoidance of contraindicated combinations like nitrates or riociguat.

Spedra’s 50/100/200 mg range gives UK clinicians flexibility for individualised titration.

Dosage Strategy

How should avana be started and adjusted for common clinical situations?

General Dosing

Standard on‑demand dosing in the UK is to start at 100 mg taken about 15 minutes before sexual activity, with or without food.

Available tablet strengths are 50 mg, 100 mg and 200 mg, allowing stepwise titration.

If 100 mg is ineffective or poorly tolerated, reduce to 50 mg for tolerability or interactions, or increase to 200 mg if needed and tolerated.

Maximum frequency is once daily and daily dosing beyond that is not recommended.

Condition‑Specific Dosing

Elderly patients do not require automatic dose reduction but warrant careful monitoring and consideration of a 50 mg start if comorbidities or polypharmacy are present.

In mild to moderate hepatic impairment, use a lower initial dose and avoid use in severe hepatic impairment.

Mild to moderate renal impairment usually does not require dose change, but exercise caution and clinical judgement in severe renal dysfunction.

Always assess for CYP3A4 inhibitors, cardiovascular risk and counsel patients on expected onset, including that many report response within 15 minutes.

Safety Protocols

Who must not take avana, and what side effects should patients watch for?

Contraindications

Absolute contraindications include concurrent nitrate therapy because of the risk of life‑threatening hypotension.

Also avoid use with guanylate cyclase stimulators such as riociguat, in known hypersensitivity to avanafil or excipients, in severe cardiovascular instability, and in severe hepatic impairment.

UK prescribers must perform a full medication reconciliation before issuing Spedra to ensure safety.

Adverse Effects

Most common effects are mild and include headache, flushing, nasal congestion, back pain and dizziness.

Less common but relevant effects include symptomatic hypotension, visual disturbances and palpitations.

Priapism (erection lasting more than four hours) is rare but a urological emergency; men with conditions predisposing to priapism should be counselled closely.

Encourage reporting of suspected adverse reactions via the MHRA Yellow Card scheme to support pharmacovigilance.

Interaction Mapping

What should patients avoid taking with avana to stay safe?

Food Interactions

Avanafil can be taken with or without food, but a high‑fat meal may delay Tmax and slow the onset for some patients.

Advise taking Spedra on a relatively empty stomach when a rapid onset is desired.

Drug Combinations To Avoid

Avoid nitrates at all costs because of profound hypotension risk.

Do not co‑prescribe riociguat, a guanylate cyclase stimulator, for the same reason.

Strong CYP3A4 inhibitors such as ketoconazole, itraconazole and ritonavir increase avanafil exposure — consider a 50 mg starting dose or avoid use.

Moderate CYP3A4 inducers like rifampicin may reduce efficacy and require clinical judgement.

Alpha‑blockers carry an additive hypotension risk; if co‑administration is necessary, start low and monitor blood pressure carefully for orthostatic symptoms.

Patients should provide a complete medication list including over‑the‑counter products and herbal remedies such as St John’s Wort which can interact via CYP pathways.

Patient Experience Analysis

What do men say about Spedra in surveys and online forums?

Survey Data

Clinic audits and patient‑reported outcome studies consistently report high satisfaction with avanafil’s rapid onset and timing convenience.

UK patients often highlight the 15‑minute window as a practical advantage over slower onset options, and discontinuation rates are lower among those who prioritise spontaneity.

Common reasons for stopping remain tolerability issues such as headache and flushing.

Forum Trends

Online forums show recurring themes of preference for Spedra for spontaneity, concerns about cost and NHS versus private prescribing, and questions about switching from sildenafil or tadalafil.

Misinformation about dangerous interactions and overuse appears online, so clinicians should correct myths during consultations and point patients to reliable NHS and MHRA resources.

Shared decision‑making, clear counselling about onset and side effects, and realistic expectations usually improve adherence and satisfaction.

Distribution And Pricing Landscape

How accessible is Spedra across the UK and what does it typically cost?

In the UK market avanafil is marketed as Spedra in 50 mg, 100 mg and 200 mg foil blister tablets, typically distributed by Menarini or licensed distributors.

It is prescription‑only and availability on the NHS is limited and varies across local formularies and integrated care systems.

Most access in practice comes through private clinics and community pharmacies, where private market prices are generally higher than older PDE5 inhibitors with available generics such as sildenafil.

As of August 2025 there are no widely available generics for avanafil in major markets, so branded price points persist.

Manufacturers supply blister packs to wholesalers and community pharmacies; storage recommendations are 20–25°C as per product information.

Clinicians should check local formulary policies and patient access programmes when discussing cost and procurement with patients.

In our online pharmacy, avana is available without a prescription, with discreet delivery to United Kingdom in 5-14 days.

Alternative Options

How does avanafil compare with other PDE5 inhibitors and when might you choose a different drug?

Comparison Table

Sildenafil (Viagra) is longer established and commonly used but generally has a slower onset and more PDE6 cross‑reactivity leading to visual disturbance reports.

Tadalafil (Cialis) has the longest half‑life and can be used in a daily dosing strategy for men with frequent sexual activity needs, but onset is typically slower.

Vardenafil (Levitra) has an onset similar to sildenafil with a variable side‑effect profile for some men.

Avanafil (Spedra/Stendra) occupies a niche for patients prioritising faster onset — some report effect within 15 minutes — with a lower visual side‑effect signal and flexible 50/100/200 mg dosing.

Pros And Cons

Advantages of avanafil include rapid onset, generally favourable tolerability and flexible dosing options for titration.

Limitations include branded pricing without widespread generics and less long‑term real‑world data compared with older PDE5 inhibitors.

Class contraindications apply to all PDE5 inhibitors, so choice depends on patient priorities, comorbidities and prior PDE5 experiences.

Regulatory Status

Is avana authorised and how is it classified?

Avanafil is authorised internationally under brand names Spedra in the EU, UK, Australia and much of the world, and Stendra in the US and Canada.

Key regulatory milestones include FDA approval for Stendra in 2012 and EMA authorisation for Spedra in 2013, with UK availability following EMA/MHRA frameworks.

Across listed markets avanafil is prescription‑only and marketed in strengths of 50 mg, 100 mg and 200 mg with labelling and storage guidance to store at 20–25°C.

Pharmacovigilance for Spedra is via MHRA Yellow Card reporting in the UK and manufacturers maintain risk‑management plans addressing key contraindications.

As of August 2025 no widespread generics are available in the EU, US or Canada, sustaining the branded market position.

Consolidated FAQ

Which questions do patients and prescribers ask most about Spedra?

Key Patient Questions

How quickly does it work?

Many men respond within 15 minutes, so typical advice is to take about 15 minutes before sexual activity with 100 mg as the general starting dose.

Can I take it with food?

Yes, but a high‑fat meal may delay onset and slow the effect.

What doses are available?

Spedra tablets in the UK are supplied in 50 mg, 100 mg and 200 mg blister packs.

Is it safe with my heart medication?

Avoid nitrates and riociguat and check for CYP3A4 inhibitors and alpha‑blockers; consult your prescriber for a full review of interactions.

Prescriber Questions

What starting dose is recommended?

Start at 100 mg for most patients and adjust to 50 mg for interaction or tolerability concerns or to 200 mg if 100 mg is ineffective and well tolerated.

How often can it be taken?

On‑demand use is advised with a maximum frequency of once daily.

Any special population notes?

Avoid in severe hepatic impairment, use caution in severe renal disease and document counselling and follow up; report suspected adverse events via Yellow Card.

Visual Guide

How can patients reliably identify Spedra and remember safety points?

Tablet Identification And Packaging

Spedra tablets in the UK arrive in foil blister strips marked with the product name and dosage, and the pack includes a patient information leaflet.

Available strengths are 50 mg, 100 mg and 200 mg, and storage guidance is printed on the leaflet and pack.

User Counselling Visuals (Suggested)

Simple timing visuals help patients remember to take 100 mg around 15 minutes before activity or 50 mg about 30 minutes before when a slower onset is expected.

Interaction visuals should clearly show a red cross for nitrates and riociguat and a pill bottle icon for CYP3A4 interacting medicines.

Side‑effect icons can illustrate headache, flushing and nasal congestion and include an emergency icon for priapism to prompt urgent care.

Pharmacists and clinicians can provide laminated cards or PDFs so patients match the blister pack to safe use instructions in primary care or sexual health settings.

Storage And Transport

How should pharmacies and patients store Spedra to keep it effective?

Store Spedra tablets at controlled room temperature between 20–25°C with permitted excursions to 15–30°C as per product information.

Keep tablets in the original light‑protective blister until use and avoid refrigeration or freezing.

Pharmacies should store stock in a secure dispensary, rotate by expiry date and monitor ambient temperature to protect supply chain integrity.

During transport protect blister packs from prolonged heat and moisture and use authorised couriers for longer journeys.

Advise patients to store packs away from direct heat and humidity and out of reach of children, and to return unused medicine to a pharmacy for safe disposal rather than flushing.

Guidelines For Proper Use

What checklist should prescribers follow and what instructions should patients get at the consultation?

Prescriber Checklist

Confirm an erectile dysfunction diagnosis and perform a cardiovascular risk assessment before prescribing avanafil.

Review all medications and avoid nitrates and riociguat.

Choose a starting dose (100 mg typical; 50 mg for interaction or tolerability concerns) and counsel on timing and side effects.

Document consent for any off‑label use and report safety signals via the MHRA Yellow Card system.

Patient Instructions

Use avanafil on‑demand only and do not combine with nitrates or riociguat.

Avoid excessive alcohol and be aware that a heavy fatty meal can delay onset.

Seek immediate care for erections lasting more than four hours or sudden loss of vision or hearing.

Store medication in the original blister at room temperature and return any unwanted medication to a pharmacy for safe disposal.

Arrange a brief follow‑up after several doses to reassess efficacy and tolerability and consider dose adjustment within the 50/100/200 mg range if needed.

Delivery Across United Kingdom

Final Practical Notes

Many men ask whether avanafil affects fertility or protects against sexually transmitted infections.

Avanafil does not affect fertility, sperm motility, nor does it provide any protection against STIs, and it is not indicated for use in children or women.

When discussing treatment options with patients, consider speed of onset, side‑effect profile and cost, and compare Spedra against sildenafil, tadalafil and vardenafil based on those priorities.

Document all counselling, check concomitant medicines for CYP3A4 interactions, and remind patients to report adverse effects via the MHRA Yellow Card system.

For private patients in the UK, consider local formulary options and explain that branded Spedra remains more expensive than older generics such as sildenafil when available.

When in doubt about cardiovascular safety, seek cardiology advice before prescribing any PDE5 inhibitor, including avanafil.